Literature summary for 3.4.21.77 extracted from

Zhu, L.; Jaeaemaa, S.; Af Haellstroem, T.M.; Laiho, M.; Sankila, A.; Nordling, S.; Stenman, U.H.; Koistinen, H.
PSA forms complexes with alpha1-antichymotrypsin in prostate (2013), Prostate, 73, 219-226.

Search for more literature for 3.4.21.77

Application

Application	Comment	Organism
diagnostics	the enzyme is the most useful prostate cancer marker	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
alpha1-Aantichymotrypsin	in circulation, the majority of the enzyme is complexed with protease inhibitors, including alpha1-antichymotrypsin. The proportion of the enzyme-alpha1-antichymotrypsin complex is higher in patients with prostate cancer than in controls without cancer	Homo sapiens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
extracellular	the enzyme is secreted by human prostate tissues	Homo sapiens	-	-

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	P07288	-	-

Purification (Commentary)

Purification (Comment)	Organism
native active enzyme from seminal plasma by immunoaffinity chromatography and anion-exchange chromatography	Homo sapiens

Source Tissue

Source Tissue	Comment	Organism	Textmining
prostate	the enzyme forms complexes with alpha1-antichymotrypsin in prostate	Homo sapiens	-
prostate cancer cell	the enzyme forms complexes with alpha1-antichymotrypsin in prostate	Homo sapiens	-

Subunits

Subunits	Comment	Organism
?	x * 22000-30000, active enzyme, SDS-PAGE	Homo sapiens

Synonyms

Synonyms	Comment	Organism
prostate-specific antigen	-	Homo sapiens
PSA	-	Homo sapiens

General Information

General Information	Comment	Organism
additional information	in circulation, the majority of the enzyme is complexed with protease inhibitors, including alpha1-antichymotrypsin. The proportion of the enzyme-alpha1-antichymotrypsin complex is higher in patients with prostate cancer than in controls without cancer	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)